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Acromegaly is debilitating disease occasionally refractory to surgical and medical treatment. Stereotactic radiosurgery, and in
particular Gamma Knife surgery (GKS), has proven to be an eﬀective noninvasive adjunct to traditional treatments, leading
to disease remission in a substantial proportion of patients. Such remission holds the promise of eliminating the need for
expensive medications, along with side eﬀects, as well as sparing patients the damaging sequelae of uncontrolled acromegaly.
Numerous studies of radiosurgical treatments for acromegaly have been carried out. These illustrate an overall remission rate over
40%. Morbidity from radiosurgery is infrequent but can include cranial nerve palsies and hypopituitarism. Overall, stereotactic
radiosurgery is a promising therapy for patients with acromegaly and deserves further study to reﬁne its role in the treatment of
aﬀected patients.
1.Introduction
Acromegaly is serious endocrinological derangement which,
left untreated, reduces life expectancy and results in physio-
logical derangements and complications that may negatively
aﬀect a patient’s quality of life. The ﬁrst line of treatment is
typically surgical resection of the tumor causing acromegaly.
Those patients with residual or recurrent disease are
often treated with medication to decrease growth hormone
secretion or block its action on peripheral tissues. These
treatments are not universally eﬀective for patients and are
sometimes contraindicated. As an adjunct treatment, and
sometimes as an alternative treatment, radiosurgery has
proven to be an attractive therapy. It is noninvasive, has few
side eﬀects, and is available in many centers internationally
[1–3]. In the current paper, we ﬁrst describe the patho-
physiology of acromegaly, the existing surgical and medical
treatments, and then introduce radiosurgical methods. In
particular,wewillfocusongammakniferadiosurgery(GKS)
since it has a broader base of supporting literature than
alternative forms of stereotactic radiosurgery. Finally, the
overall eﬃcacy of GKS is described, along with its reported
morbidities.
2. Acromegaly
Acromegaly is a syndrome caused by elevated levels of cir-
culating growth hormone (GH). The most common cause
of the disorder, accounting for about 98% of cases, is a
GH-secreting pituitary adenoma. Rare nonpituitary causes
of acromegaly include diverse entities such as hypothalamic
hamartomas, small-cell lung cancers, pheochromocytomas,
and bronchial carcinoids. Among GH-secreting pituitary
adenomas, roughly 60% are pure GH-secreting somatotrope
adenomas, while the remainder are mixed mammosoma-
totropes, which secrete both GH and prolactin (PRL) and
sometimes thyroid-stimulating hormone (TSH) [4].
The symptoms of increased GH are mediated by both the
direct eﬀects of GH binding to the GH receptor, activating
theJAK/STATpathway,andindirectlyviainsulin-likegrowth
factor 1 (IGF-1). IGF-1 is synthesized predominantly in
the liver under the control of GH. The combined eﬀects
of GH and IGF-1 on target tissues lead to bony and soft
tissue growth, noted by a characteristic constellation of signs
including frontal bossing, prognathism, widely spaced teeth
(due to mandibular growth), increased shoe or ring sizes,2 International Journal of Endocrinology
skin tags, carpal tunnel syndrome, and coarse facial features
[4].
These externally recognizable signs in themselves are not
asimportanttooverallmorbidityasinternalchanges,includ-
ing cardiomegaly and visceromegaly [4, 5]. Diabetes mellitus
occurs in roughly 25% of patients, and cardiomyopathy with
arrhythmia, hypertension, and diastolic dysfunction occurs
in 30%. Additionally, colonic polyps are more frequent, as
is sleep apnea which occurs in 60% of patients, presumably
secondary to soft tissue expansion and macroglossia. When
uncontrolled, acromegaly reduces life expectancy by 10 years
[4].
The prevalence of acromegaly is uncertain. Multiple
studies through the 1920s to 1990s agreed on a prevalence
of roughly 60 per million, a mean age of onset of 44 years,
symptoms lasting on average 8 years before diagnosis, and
no diﬀerence in incidence between men and women [6].
However, more recent studies place the prevalence at 86 per
million [7], 124 per million [8], and a remarkably high 1034
per million [9]. However, in addition to being geographically
and demographically restricted (primary care patients in
Germany), this last study was based on a biochemical
deﬁnition of acromegaly (elevated IGF-1 and GH) rather
than a syndrome deﬁnition, and therefore will include many
patients who would otherwise not seek treatment [9]. Such a
more liberal deﬁnition might be one method of discovering
at-risk patients earlier in the course of their disease and
permitting more time to mitigate the accruing morbidity.
3.ConventionalTreatment
Surgery is typically the ﬁrst line of treatment for acromegaly
due to pituitary adenomas provided there are no surgical
contraindications. Residual disease is then managed medi-
callywithsomatostatinanalogues,dopamineagonists,orGH
receptor antagonists [10].
3.1. Surgical. Most adenomas are resected via the transsphe-
noidal approach (transsphenoidal adenomectomy, TSA).
Using either a microscope or endoscope, the surgeon enters
the sphenoid sinus transnasally, then penetrates the sella,
and ﬁnally debulks and removes the tumor, sparing as much
of the normal pituitary as possible. For microadenomas
(<10mm in diameter), TSAs lead to correction of GH
levels in ∼70% of patients [11]. Only 50% of patients with
macroadenomas achieve normalization [11].
3.2. Medical. For those patients who do not experience
normalization of GH levels after surgery, or who are not
surgical candidates, medical therapy is initiated. The ﬁrst
drug is usually a somatostatin analogue such as octreotide
or lanreotide. The LAR (long-acting release) formulation
of octreotide uses polymeric microspheres and is injected
monthly [12]. Lanreotide ATG (autogel) is the only formu-
lation of lanreotide currently available in the United States
and is suspended in aqueous solution in microsyringes for
subcutaneous delivery by the patient. The two formulations
appear to be equally eﬃcacious and normalize IGF-I levels in
50–60% of patients [13–16]. Somatostatin analogues appear
toinducetumorshrinkageinapproximately42%ofpatients,
when data are pooled across studies [17]. Interestingly,
however, tumor shrinkage appears more pronounced in
primarily treated patients (52%) as opposed to patients
receiving adjunctive, postsurgical treatment (21%) [17].
Dopamine agonists appear to work best in patients
whose tumors also secrete prolactin [18]. Among dopamine
agonists, cabergoline appears to be the most eﬃcacious,
resulting in normalization of IGF-I levels in 34% of patients
[19]. However, no dopamine agonist alone is as eﬀective as
a somatostatin analogue [20], although there might be syn-
ergistic eﬀects when used in conjunction with somatostatin
analogues [21–24].
Pegvisomant is a PEGylated growth hormone analogue
that is subcutaneously injected by patients. In one study,
treatment for 12 months led to normalized IGF-1 levels
in 97% of patients [25], and treatment for 24 months
led to normalization in 76.3% of patients in a diﬀerent
study [26]. However, the side eﬀects of pegvisomant include
transaminitis, lipodystrophy at injection sites, and, most
worrisome, possible tumor progression, due to blocking of
the normal inhibitory feedback of growth hormone levels of
the adenoma [27–29].
4. Radiosurgery
4.1. Technology. Simply put, resective surgery is a means
of removing unwanted tissue from the body. Radiosurgery
(RS) achieves the identical goal but, rather than directly
removing cells, induces cell death instead. This cell death
can be induced either directly, via necrosis or apoptosis,
or indirectly, by damaging the tissue blood supply. When
inducing cell death, RS uses ionizing radiation, wherein
charged particles or photons strip electrons from atoms
and molecules, thereby damaging DNA, proteins, and other
molecules within cells and in the extracellular matrix.
When this damage cannot be repaired, cells undergo either
apoptosis or necrosis [30, 31].
Various types of radiosurgery are available, but each
works by emitting charged particles or photons. Proton
beams, for example, generated by particle accelerators and
can be used to target structures deep within the cranium.
Thisis due,in part,to thecharacteristicpeakand subsequent
drop-oﬀ of radiation intensity in proton beams—the Bragg
peak [31]. The depth of this peak can be modulated and
is used to focus the eﬀects of the radiation on particular
structures, sparing healthy ones. The drawback to proton
therapy, however, is the high cost and relative scarcity of
facilities capable of providing therapeutic proton beams
[32].
Photons, on the other hand, are much more commonly
used for radiosurgery. The two major techniques are linear
accelerators and radioactive isotopes. Linear accelerators,
like the CyberKnife (Accuray Inc., Sunnyvale, CA), produce
photons which are then aimed toward deep structures within
the brain or spine. To limit damage along the path of the
beam, a weak beam is used and moved around the patient.International Journal of Endocrinology 3
Table 1: Studies of GKS for acromegaly.
Study No. of
patients Mean follow-up (mos.) Dose (Gy) No. of remission
(%)
Iwai et al., 2010 [42] 26 84 20.2 10 (38)
Ronchi et al., 2009 [43] 28 103 20 19 (96)
Swords et al., 2009 [44] 10 38.5 10 3 (30)
Wan et al., 2009 [45] 103 67 21.4 38 (37)
Jagannathan et al., 2009 [46] 95 57 22 50 (53)
Losa et al., 2008 [47] 83 69 25 50 (60)
Pollock et al., 2008 [48] 27 48 20 18 (67)
Vik-Mo et al., 2007 [34] 53 66 26.5 9 (17)
Jeˇ zkov´ a et al., 2006 [49] 96 54 32 48 (50)
Castinetti et al., 2005 [50] 82 49.5 25.7 14 (17)
Kobayashi et al., 2005 [40] 67 63 18.9 7 (10)
Attanasio et al., 2003 [51] 30 46 20 7 (23)
Choi et al., 2003 [52] 12 42.5 28.5 6 (50)
Jane Jr. et al., 2003 [53]6 4 >18 15 23 (36)
Petrovich et al., 2003 [54] 6 41 15 6 (100)
Ikeda et al., 2001 [55] 17 56 25 14 (82)
Fukuoka et al., 2001 [56] 9 42 20 4 (44)
Izawa et al., 2000 [57]2 9 >6 22.5 12 (41)
Shin et al., 2000 [58] 6 43 34.4 4 (67)
Zhang et al., 2000 [59] 26 36 31.3 25 (96)
Inoue et al., 1999 [60]1 2>24 20.9 7 (58)
Kim et al., 1999 [61] 2 12 22 0 (0)
Kim et al., 1999 [62] 11 27 28.7 5 (45)
Mokry et al., 1999 [63] 10 46 16 4 (40)
Lim et al., 1998 [64] 16 25.5 25.4 6 (38)
Martinez et al., 1998 [65] 7 36 24.7 6 (86)
Morange-Ramosa et al., 1998
[66] 15 20 28.7 3 (20)
Pan et al., 1998 [67] 15 29 28.6 15 (100)
Park et al., 1996 [68] 7 15 27.1 4 (57)
Total 964 417 (43)
Thus, the target of the beam is constant, always receiving
radiation, but the intervening structures are exposed only
brieﬂy [30–32].
The Gamma Knife (Elekta AB, Stockholm, Sweden),
developed by Lars Leksell in 1968, uses 201 sources of
radioactive cobalt-60 [32]. Each source generates a beam of
photons as the cobalt decays, and these beams are focused
on a central target within the brain through the use of col-
limators. Because each individual beam is weak, intervening
tissue is exposed to far less radiation than the central target,
which is the common focus of all 201 beams. The Gamma
Knife has been around longer than most linear accelerator
radiosurgicaldevicesandisthereforeabetter-studiedtoolfor
use by neurosurgeons, though direct comparisons between
the Gamma Knife and linear accelerators will undoubtedly
change the prevailing practices in the future. The remainder
of this paper will focus exclusively on GKS.
4.2. Clinical Studies. A large number of small case series
have been carried out to evaluate the eﬀects of Gamma
Knife surgery (GKS) on acromegaly (Table 1). Most use
remission criterion of a normal IGF-1 level and many
add the criterion GH < 1 to 2ng/mL, but it should be
noted that remission criteria vary across studies. These
criteria are roughly in line with the criteria set forth by
the Acromegaly Consensus Group on 2010 (normal IGF-
1a n dG H< 1ng/mL) [33]. Also variable between studies
is the follow-up time, along with radiation dose, targeting
protocol,and,mostcritically,pre-GKStherapy.Thislastnote
is particularly important since most series include patients
who have already received transsphenoidal surgical resection
as an inadequate treatment. Unfortunately, the data are not
presented in the reviewed papers in such a way as to separate
out response rates in patients receiving prior treatment
versus those who were treated primarily with GKS.4 International Journal of Endocrinology
Table 2: Adverse events of GKS for acromegaly.
Study Hypopituitarism (%) Headache (%) Radiation necrosis (%) Visual changes (%)
Iwai et al., 2010 [42] 2 (8) 1 (4) 1 (4) 0
Ronchi et al., 2009 [43]— — — 0
Swords et al., 2009 [44] 3 (12) 0 0
Wan et al., 2009 [45]6 ( 6 ) — 2 ( 2 ) 0
Jagannathan et al., 2009 [46] 32 (34) — — 4 (4)
Losa et al., 2008 [47] 7 (9) 5 (6) — 0
Pollock et al., 2008 [48] 16 (36) — — 1 (2)
Vik-Mo et al., 2007 [34] 14 (23) — — —
Jeˇ zkov´ a et al., 2006 [49] 26 (43) — — —
Castinetti et al., 2005 [50] 14 (17) — — 1 (1)
Kobayashi et al., 2005 [40] 39 (15)∗ — — 29 (11)∗
Attanasio et al., 2003 [51] 2 (7) 1 (3) — 0
Choi et al., 2003 [52]0 — — 0
Jane Jr. et al., 2003 [53] 18 (28) — — —
Petrovich et al., 2003 [54]2 ( 3 ) ∗ 2( 3 ) ∗ —3 ( 4 ) ∗
Ikeda et al., 2001 [55]0 — — 0
Fukuoka et al., 2001 [56]0 — — 0
Izawa et al., 2000 [57] 1( 3 ) — 1( 3 ) 1( 3 )
Shin et al., 2000 [58]1 ( 6 ) ∗ —— 1 ( 6 ) ∗
Zhang et al., 2000 [59]— — ——
Inoue et al., 1999 [60]— — ——
Kim et al., 1999 [61]— — — —
Kim et al., 1999 [62]— — 0 0
Mokry et al., 1999 [63] 3 (19) — — 0
Lim et al., 1998 [64]1 ( 2 ) ∗ 18 (28)∗ —1 ( 2 ) ∗
Martinez et al., 1998 [65]0 — —1 ( 3 ) ∗
Morange-Ramosa et al., 1998
[66] 4 (16)∗ —— 1 ( 4 ) ∗
Pan et al., 1998 [67]— — — —
Park et al., 1996 [68]0 — 0 0
Total (%) 191 (16) 27 (12) 4 (2) 43 (4)
∗Numbers of GKS for all treated pituitary tumor types (not reported for acromegalic patients alone).
Overall, however, the results from these studies suggest
that GKS is an eﬀective treatment for acromegaly. Across the
29 studies and 964 cases examined, 43% of patients achieved
remission. The time to remission is not reliably reported,
but most studies agree that the further out from RS patients
are examined, the more likely they are to achieve a cure.
This eﬀect, intriguingly, does not seem to have a ceiling. For
example, Vik-Mo et al. [34] showed an increase from 58% of
patients with normal IGH-1 levels to 86% of patients over
the time span of 5 to 10 years after RS. How exactly the
eﬀectsof RS continue to evolve over such a protracted time is
unknown, but consistent with how RS aﬀects other diseases,
like epilepsy [35] and vestibular schwannoma [36].
Interestingly, there is some (still debated) evidence that
the use of antiacromegalic medicines prior to irradiation
attenuates the eﬀects of GKS [1]. That is, using somatostatin
analogues or GH receptor antagonists has been shown in
select studies to decrease a patient’s chances of remission
[37–39].Thoughthishasnotbeenthoroughlyexamined,the
mechanism is believed to be suppression of tumor cell cycle,
thereby making the cells less prone to radiation-induced
damage.
There does not appear to be a correlation between radia-
tion dose and rates of remission (Figure 1). However, the
heterogeneity in study design, follow-up, and deﬁnition of
remission makes such conclusions fraught.
4.3. Morbidity. The most common complication of GKS for
acromegaly is hypopituitarism, presumably from damage to
the normal gland during irradiation, ranging from 0 to 43%
[1]( Table 2). However, the degree to which such damage is
a pure result of GKS versus prior surgery, if done, is unclear
[1]. Moreover, there is no discernible relationship between
radiation dose and the incidence of this complicationInternational Journal of Endocrinology 5
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Figure 1: Eﬀect of GKS dose on remission. The percentage of
patientsinremissionisplottedasafunctionofthedoseusedduring
GKS. There is no signiﬁcant trend, though the heterogeneity of the
studies makes it diﬃcult to draw deﬁnite conclusions.
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Figure 2: Eﬀect of GKS dose on hypopituitarism as an adverse
event. The rate of hypopituitarism is shown as a function of
GKS dose for each study. There is no deﬁnite relationship. Again,
however, the heterogeneity in study design, follow-up, and other
parameters makes it diﬃcult to draw deﬁnitive conclusions from
this summary.
(Figure 2), though these are very heterogeneous studies
and it is possible that better-controlled or larger studies
would uncover such relationships if they exist.
Other complications are inadequately documented but
includeheadache,epilepsy,carotidarterystenosis,and,more
frequently, cranial nerve palsies or neuropathies (including
trigeminal neuralgia and visual decline) [1]( Table 2). The
rateofvisualdisturbancesseemstobe,intheworstcase,11%
[40,41],thoughmosttrialseitherdonotreporttheseadverse
events or show them to be on the order of 0–6% (Table 2).
Nevertheless, these complications should be viewed in
light of the complications inherent to uncontrolled acro-
megaly or, if being used as an alternative to surgery, the
morbidity of an endonasal neurosurgical procedure.
5. Conclusions
Acromegaly is a serious disorder leading to increased mor-
bidity and mortality in patients. While surgical resection
remains the ﬁrst line of treatment, stereotactic radiosurgery
is proving itself a feasible alternative therapy (when surgery
might be contraindicated) and adjunct (when surgical
resection is unsuccessful in leading to complete disease
remission). GKS is very eﬀective, leading to remission in
over 40% of cases. But it is clearly not universally eﬀective.
Ultimately, further studies are needed to delineate which
patients are most likely to receive beneﬁt from GKS, along
with ways to improve GKS outcomes.
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